Use of Inhaled Corticosteroids and Risk of Acquiring Haemophilus influenzae in Patients with Chronic Obstructive Pulmonary Disease
Authors:
- Raza Ul MohsinRMRaza Ul Mohsin
- Christian Kjer HeerfordtCHChristian Kjer Heerfordt
- Josefin EklöfJEJosefin Eklöf
- Pradeesh SivapalanPradeesh Sivapalan
- Mohamad Isam SaeedMSMohamad Isam Saeed
- Truls Sylvan IngebrigtsenTITruls Sylvan Ingebrigtsen
- Susanne Dam NielsenSNSusanne Dam Nielsen
- Zitta Barrella HarboeZitta Barrella Harboe
- Kasper Karmark IversenKIKasper Karmark Iversen
- Jette BangsborgJBJette Bangsborg
- Jens Otto JarløvJJJens Otto Jarløv
- Jonas Bredtoft BoelJBJonas Bredtoft Boel
Open Access
- 20 June 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3539
Abstract
Background: Inhaled corticosteroids (ICS) are widely used in chronic obstructive pulmonary disease (COPD), despite the known risk of severe adverse effects including pulmonary infections. Research Question: Our study investigates the risk of acquiring a positive Haemophilus influenzae airway culture with use of ICS in outpatients with COPD. Study Design and Methods: We conducted an epidemiological cohort study using data from 1 January 2010 to 19 February 2018, including 21,218 outpatients with COPD in Denmark. ICS use 365 days prior to cohort entry was categorised into low, moderate, and high, based on cumulated ICS dose extracted from a national registry on reimbursed prescriptions. A Cox proportional hazards regression model was used to assess the future risk of acquiring H. Influenzae within 365 days from cohort entry, and sensitivity analyses were performed using propensity score matched models. Results: In total, 801 (3.8%) patients acquired H. Influenzae during follow-up. Use of ICS was associated with a dose-dependent increased risk of acquiring H. Influenzae with hazard ratio (HR) 1.2 (95% confidence interval (CI) 0.9–1.5, p value = 0.1) for low-dose ICS; HR 1.7 (95% CI 1.3–2.1, p value < 0.0001) for moderate dose; and HR 1.9 (95% CI 1.5–2.4, p value < 0.0001) for high-dose ICS compared to no ICS use. Results were confirmed in the propensity-matched model using the same categories. Conclusions: ICS use in outpatients with COPD was associated with a dose-dependent increase in risk of isolating H. Influenzae. This observation supports that high dose ICS should be used with caution.Keywords
Funding Information
- Novo Nordisk Fonden (NNF20OC0060657, 0134-00257A)
- Research committee at Herlev and Gentofte University Hospital (NNF20OC0060657, 0134-00257A)
- Herlev and Gentofte Hospital, University of Copenhagen (NNF20OC0060657, 0134-00257A)
- Independent Research Denmark (NNF20OC0060657, 0134-00257A)
This publication has 33 references indexed in Scilit:
- Chronic Exposure to Glucocorticoids Shapes Gene Expression and Modulates Innate and Adaptive Activation Pathways in Macrophages with Distinct Changes in Leukocyte AttractionThe Journal of Immunology, 2014
- Inhaled corticosteroids in COPD and the risk of serious pneumoniaThorax, 2013
- Chronic bronchial infection in COPD. Is there an infective phenotype?Respiratory Medicine, 2013
- Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed PrescriptionsClinical Epidemiology, 2012
- GlucocorticoidsThe Neurohospitalist, 2012
- Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosisThorax, 2012
- Impact of exacerbations on COPDEuropean Respiratory Review, 2010
- Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and the Risk of Hospitalization for PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art ReviewClinical Microbiology Reviews, 2001